Background Image

MUCOPURE [Specialities]

MUCOPURE is a powder that contains digestive enzymes, as well as Vitamins and Minerals.
natural energy MUCOPURE
Prijs : € 37.99 Euro

(CNK: 2833-515) at your pharmacist

The intestinal mucosa has a dual role to play. It absorbs nutrients and acts as a barrier against unwanted substances.  That is exactly why the integrity of the intestinal mucosa is so important.  If it can no longer perform one of its roles, this leads to numerous health problems.

The digestive enzymes  are Bromelain, Papain, Trypsin, Lipase and Catalase.

MUCOPURE  contains ALSO  Vitamins A, B1, B3, B6, B9, B12, and Vitamine D and E. MUCOPURE is also rich in the minerals Calcium, Magnesium, Selenium and Manganese.
Finally, it also contains pure micro-algae Spirulina.


Instructions for use
2 teaspoons (= 10 g) per day the first week and then 2 tablespoons (= 30 g) per day, preferably before meals, to dissolve in liquid.
(1 teaspoon = 5 g)
(1 tablespoon = 15 g)

Do not exceed the recommended daily dose.
Keep out of reach of young children.
Nutritional supplements should not replace a varied and balanced diet and a healthy lifestyle.

Consult your doctor or pharmacist during concomitant use of anticoagulants.

Should not be used on children under the age of 12.

Children, pregnant women and women who are breastfeeding, consult your pharmacist before use.
Check with simultaneous intake of medicines.
No long-term use without professional advice.

NUT_PL_AS 1429/21


Range of usage


Ingredients per daily dose of 2 Tablespoons (30 g)
Filler, emulsifier (Soy lecithin), Spirulina platensis Geitler powder (Gomont) 350 mg, L-Glutamine 250mg, Curcuma longa l. (Turmeric) dry extract 200 mg, Magnesium (Magnesiumbisglycinaat) 168,75mg (45% RI), MSM (Methylsulfonylmethane) 80 mg, Gamma oryzanol 75mg, Alpha-Lipoic acid 50mg, Vitamin C (L-Ascorbic acid) 50mg (62.50% RI) 33mg, Amylase 33,33mg,  Protease 33,33mg, Lipase  33,33mg, Hydrastis canadensis l. (goldenseal) dry extract 20mg, Vitamin B3 (Nicotinamide) 20mg (125% RI) , N-acetyl-cysteine 10mg, L-Glutathione 10mg, Vitamin E (D-alpha-tocopheryl acetate) 5,40mg (45% RI), Vitamin B5 (Calcium-D-pantothenate) 5 mg (83.33% RI), Zinc (Zinkbisglycinaat) 4,5mg (45% RI), Vitamin B6 (Pyridoxine HCL) 1mg (71.43% RI), Manganese (Mangaanbisglycinaat) 0,95mg (47.50% RI), Vitamin B1 (Thiamine HCL) 0,50mg (45.46% RI), Vitamin A (Retinylacetaat) 360mcg (45% RI), Vitamin H (Biotin) 300mcg (600% RI), Vitamin M (Folic acid) 90mcg  (Folic acid) 90mcg (45% RI), Selenium (as L-Selenomethionine) 24,75mcg (45% RI), Vitamin D3 (Cholecalciferol) 2, 25mcg (45% RI), Vitamin B12 (Methylcobalamin) 1,13mcg (45% RI)

RI: Reference intakes
10/1/01 Glutamine and cancer. J Nutr 2001 Sep;131(9):2539S-42S Medina M.
10/1/01 Effects of glutamine on tumor growth and apoptosis of hepatoma cells. Acta Pharmacol Sin 2000 Jul;21(7):668-72 Liu SL, Shi DY, Shen ZH, Wu YD. CONCLUSION: Hepatoma cell apoptosis and tumor growth inhibition by GLN may be associated with its antioxidative activity and its intervention in hepatoma cell proliferation, and simultaneous release of NO
10/1/01 Neovascularisation offers a new perspective to glutamine related therapy Indian J Exp Biol 2000 Jan;38(1):88-90 Maity P, Chakraborty S, Bhattacharya P Result indicates that the purified S-180 cell glutaminase reduces tumor volume and restrict the generation of neo blood vessels. Therefore, it can be concluded that this enzyme may be an effective device against the cancer metastasis.
10/1/01 Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial Gut 2001 Jan;48(1):28-33 Daniele B, Perrone F, Gallo C, Pignata S, De Martino S, De Vivo R, Barletta E, Tambaro R, Abbiati R, D'Agostino L METHODS: Seventy chemotherapy naive patients with colorectal cancer were randomly assigned to oral glutamine (18 g/day) or placebo before the first cycle of FU (450 mg/m(2)) and FA (100 mg/m(2)) administered intravenously for five days Average AUC of diarrhoea (1.9 v 4.5; p=0.09) and average number of loperamide tablets taken (0.4 v 2.6; p=0.002) were reduced in the glutamine arm. CONCLUSIONS: Glutamine reduces changes in IA and IP induced by FU and may have a protective effect on FU induced diarrhoea
10/1/01 Glutamine for irinotecan diarrhea J Clin Oncol 2000 Jan;18(2):450-1 Savarese D, Al-Zoubi A, Boucher J. (Letter- No Abstract)
Maity P, Chakraborty S, Bhattacharya P, Sarkar R. Isolation and purification of phosphate dependent glutaminase from sarcoma-180 tumor and its antineoplastic effects on murine model system. J Exp Clin Cancer Res. 1999 Dec;18(4):475-80.
Maity P, Chakraborty S, Bhattacharya P. Neovascularisation offers a new perspective to glutamine related therapy. Indian J Exp Biol. 2000 Jan;38(1):88-90.
Maity P, Chakraborty S, Bhattacharya P. A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase. J Exp Clin Cancer Res. 2000 Jun;19(2):161-4.
[Treatment of intestinal insufficiency syndrome in patients with peritonitis] Khirurgiia (Mosk). 2004;(10):31-3.
Angele P, Faltermeier H, Kujat R, Maghsudi M, Moller HD, Nerlich M. [Improvement of the amplification rate of human chondrocytes with IGF-I and RGD] Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):205-8.
Mangiante G, Marini F, Acerbi A, Marini P, Grigolini G, Azzolini P, Colombari R, Serio G. [Postoperative ischemic ileocolitis in the elderly. Suggested therapy with intraluminal administration of oxygen and glutamine] Chir Ital. 1994;46(6):80-5.
Ziegler TR. Glutamine supplementation in cancer patients receiving bone marrow transplantation and high dose chemotherapy. J Nutr. 2001 Sep;131(9 Suppl):2578S-84S; discussion 2590S.
Daniele B, Perrone F, Gallo C, Pignata S, De Martino S, De Vivo R, Barletta E, Tambaro R, Abbiati R, D'Agostino L. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001 Jan;48(1):28-33.
Liu SL, Shi DY, Shen ZH, Wu YD. Effects of glutamine on tumor growth and apoptosis of hepatoma cells. Acta Pharmacol Sin. 2000 Jul;21(7):668-72.
Schmittgen TD, Koolemans-Beynen A, Webb TE, Rosol TJ, Au JL. Effects of 5-fluorouracil, leucovorin, and glucarate in rat colon-tumor explants. Cancer Chemother Pharmacol. 1992;30(1):25-30.
Umehara K, Shimokawa Y, Miyamoto G. Effect of gamma-oryzanol on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull. 2004 Jul;27(7):1151-3.
Sugano M, Koba K, Tsuji E. Health benefits of rice bran oil. Anticancer Res. 1999 Sep-Oct;19(5A):3651-7.
Jariwalla RJ. Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. Drugs Exp Clin Res. 2001;27(1):17-26.
Walaszek, Z., Hanausek, M., Szemraj, J., and Adams, A.K. 1998, D-Glucarate acid as a prospective tumor marker. Meth. Mol. Med., 14, 487-495.
Walaszek, Z., Hanausek, M., Sherman, U. and Adams, A.K. 1990, Antiproliferative effect of dietary glucarate on the Sprague Dawley in rat mammary gland. Cancer Lett. 49: 51-57.
Abbou-Issa, H., Koolemans-Beynen, A., Minton, J.P. and Webb, T.E., 1989, Synergistic interaction between 13-cis-retinoic acid and glucarate: activity against rat mammary tumor induction and MCF-7 cells. Biochem. Biophys. Res. Commun.,163: 1364-1369.
Dwivedi, C., Oredipe, O.A., Barth, R.F., Downie, A.A. and Webb, T.E., 1989, Effects of the experimental chemopreventative agent, glucarate on intestinal carcinogenesis in rats. Carcinogenesis, 10: 1539-1541.
Dwivedi. C., Downie, A.A. and Webb, T.E., 1989, Modulation of chemically initiated and promoted skin tumorigenesis in CD-1 mice by dietary glucarate. J. Environ. Path. Toxicol. Oncol., 9: 253-259.
Oredipe, O.A., Barth, R.F., Hanausek-Walaszek, M., Sautins, I., Walaszek, Z. and Webb, T.E. 1987, Effects of an inhibitor of B-glucuronidase on hepatocarcinogenesis. Proc. Am. Assoc. Cancer Res., 28: 156.
Yoshimi N, Walaszek Z, Mori H, Hanausek M, Szemraj J, Slaga TJ. Inhibition of azoxymethane-induced rat colon carcinogenesis by potassium hydrogen D-glucarate. Int J Oncol. 2000 Jan;16(1):43-8.
Walaszek Z. Potential use of D-glucaric acid derivatives in cancer prevention. Cancer Lett. 1990 Oct 8;54(1-2):1-8.
Walaszek Z, Szemraj J, Narog M, Adams AK, Kilgore J, Sherman U, Hanausek M. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. Cancer Detect Prev. 1997;21(2):178-90.
Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003 Dec;29(6):501-13.
Ricky A. Sharma, Stephanie A. Euden, Sharon L. Platton, Darren N. Cooke, Aisha Shafayat, Heather R. Hewitt, Timothy H. Marczylo, Bruno Morgan, David Hemingway, Simon M. Plummer, Munir Pirmohamed, Andreas J. Gescher, and William P. Steward. Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance. Clin Cancer Res 2004 10: 6847-6854.
Aw TY, Wierzbicka G, Jones DP. Oral glutathione increases tissue glutathione in vivo. Chem Biol Interact. 1991;80(1):89-97.
Hagen TM, Wierzbicka GT, Sillau AH, Bowman BB, Jones DP. Bioavailability of dietary glutathione: effect on plasma concentration. Am J Physiol. 1990 Oct;259(4 Pt 1):G524-9.
Barbara Donnerstag et al. Reduced glutathione and S-acetylglutathione as selective apoptosis-inducing agents in cancer therapy. Cancer Letters 110 (1996) 63-70.
Beutler et al. Plasma glutathione in health and in patients with malignant disease. La Jolla, California.
Curcuma longa (turmeric). Monograph. Altern Med Rev. 2001 Sep;6 Suppl:S62-6.
Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986 Dec;24(12):651-4.
Chan MM, Huang HI, Fenton MR, Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol. 1998 Jun 15;55(12):1955-62.
Huang MT, Newmark HL, Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem Suppl. 1997;27:26-34.
Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol. 1998 Mar 15;55(6):775-83.
Sreejayan, Rao MN. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol. 1997 Jan;49(1):105-7.
Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun. 1995 Jan 17;206(2):533-40.
Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999 Sep 15;163(6):3474-83.
Levy G. Sulfate conjugation in drug metabolism: role of inorganic sulfate. Federation Proc. 1986;45:2235-2240.
Yim CY, et al. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J Immunol. 1994;152:5796-5805.
Chan NM-Y. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol. 1995;11:1551-1556.
Huang M-t, et al. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res. 1991;51:813-819.
Susan RR, et al. Induction of glutathione S-transferase activity by curcumin in mice. Drug Res. 1992;42(7):962-964.
Satoskar RR, et al. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. International J Clin Pharmacol Therapy Toxicol. 1986;24:651-654.
Fujita T, et al. Efficacy of glutamine-enriched enteral nutrition in an experimental model of mucosal ulcerative colitis. British J Surgery. 1995;82:749-751.
Khar A, Ali AM, Pardhasaradhi BV, Begum Z, Anjum R. Antitumor activity of curcumin is mediated through the induction of apoptosis in AK-5 tumor cells. FEBS Lett. 1999 Feb 19;445(1):165-8.
Babu, M. et al. Evaluation of chemoprevention of oral cancer with spirulina. 1995. Pub. in Nutrition and Cancer, Vol. 24, No. 2, 197-202. India.
Lisheng, et al. Inhibitive effect and mechanism of polysaccharide of spirulina on transplanted tumor cells in mice. 1991. Pub. in Marine Sciences, Qingdao, N.5. pp 33-38. China.
Baojiang, G. et al. Study on effect and mechanism of polysaccharides of spirulina on body immune function improvement. April 1994. South China Normal Univ. China. Pub. in Proc. of Second Asia Pacific Conf. on Algal Biotech. Univ. of Malaysia. pp 33-38. China.
Hayashi, et al. An extract from spirulina is a selective inhibitor of herpes simplex virus Type 1 Penetration into HeLa Cells. 1993. Pub. in Phytotherapy Research, Vol. 7. 76-80.
Background Image

Nature is our science.

natural energy Specialiteiten
Vegetable and bioidentical

The efficiency of all Natural Energy products is to be found in the way in which the active ingredients are adapted to be absorbed by the body as efficiently as possible.

natural energy Specialiteiten

Quality is essential to launch a safe and good product on the market. A good product contains active ingredients in a forms available to the human body so that these ingredients show positive health effects when used correctly.

natural energy Specialiteiten
Scientic research

In our laboratories these ingredients are optimized in innovative ways in order to obtain supplements that are distinguished by their exceptional efficiency and maximum safety.

Scientific hotline.

A question? Don't hesitate contact our experts.

Ask your question